Skip to main content

Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Figure 5 | BMC Neuroscience

Figure 5

From: Immunohistological detection of Chlamydia pneumoniae in the Alzheimer's disease brain

Figure 5

Immunohistochemistry using an amyloid-pre-absorbed anti- Chlamydia pneumoniae antibody. Panels A-D illustrate anti-C. pneumoniaeimmunoreactivity (red) in frontal AD tissue. The antibody for detection of C. pneumoniaeis a mouse monoclonal C. pneumoniaeantibody (Table 1, #3). Panel A illustrates the extent of anti-C. pneumoniaeimmunoreactivity with the non-pre-absorbed antibody. Panel B shows the extent of immunolabeling on the tissue when labeled with the 1-40 pre-absorbed antibody (pre-absorbed against >10 molar excess Sigma amyloid Aβ1-40 peptide). Panels C and D (higher power of panel C) show the extent of immunolabeling on the tissue when labeled with the 1-42 pre-absorbed antibody (pre-absorbed against >10 molar excess Sigma amyloid Aβ1-42 peptide). Size bar for panels A-C = 50 μm and panel D = 20 μm.

Back to article page